Mumbai, Sep 14 (Inditop.com) Hyderabad-based pharma company Suven Life Sciences Monday announced it has received patents for two new chemical entities (NCEs) from the US Patent office.
The two NCEs are for the treatment of disorders associated with neuro-degenerative diseases and the patents are valid until 2022 and 2024, respectively, the company said.
“The two molecules in the CNS (central nervous system ) arena, which are being developed for cognitive disorders, have an estimated $20 billion market potential globally. With these two patents, Suven now has a total of four granted US patents on NCEs,” Suven Life said in a regulatory statement.
The patents are for drugs used in the treatment of disorders like Alzheimer’s disease, attention deficient hyperactivity disorder, Huntington’s disease, Parkinson’s disease and schizophrenia.
